Comments on:

FDA blocks innovation in adult-stem-cell research

Back to the article » |
As politicians wrangle about the roll-out of the federal government’s newest program subsidizing and regulating health care in America, Washington regulators are stretching old laws in new directions that threaten medical innovation. On Oct. 21, the U.S. Court of Appeals for the D.C. Circuit will hear arguments in a case, USA v. Regenerative Sciences, in which the federal Food and Drug...

To learn more about commenting on and our community guidelines, please see our comments FAQ.